Merck & Co., Inc.

Merck & Co will pay an upfront of $400 million for SciBrunch’s preclinical KRAS‑G12D inhibitor SPR2015; the total value of the transaction could be up to $2.13 billion. SPR2015 is an orally available drug candidate to expand the company’s oncology portfolio. The move follows research successes with Moderna and is intended to help offset the risk from the impending patent loss of Keytruda. The stock shows strong short‑term relative strength, but the valuation is considered high. » Mere på deraktionaer.de

Merck & Co reports positive BRUNELLO results for remigromig (formerly EYE103) for the treatment of diabetic macular edema, a novel trispecific antibody that activates the Wnt signaling pathway. Citi views the data as helping to offset revenue shortfalls after Keytruda’s patent loss and expects increased investor interest in the late-stage pipeline. Remigromig came from the May 2024 acquisition of EyeBio ( $1.3bn upfront plus up to $1.7bn in milestones) and could further diversify Merck’s commercial portfolio. » Mere på deraktionaer.de

Merck & Co. is lowering dependence on its cancer blockbuster Keytruda as new products Winrevair, Welireg and Capvaxive contribute to growth and record prescription volumes. Regulatory tailwinds, including clearer federal drug pricing and faster FDA approvals, have supported pharmaceutical performance. The company’s shares have risen strongly over the past year amid these operational developments. » Mere på finance.yahoo.com